New Discovery Data Architecture Needed to Support New Modalities

Bio-IT World October 22, 2021
Contributed Commentary by David Lowis

Increasingly, the discovery and development of new medicines is embracing bioactive modalities beyond traditional small molecules, both as therapeutic agents and delivery mechanisms.

The development of medicines from any modality—small molecules, peptides, oligonucleotides, antibodies, and antibody-drug conjugates—is inherently a data-driven activity requiring the effective representation of substances, the efficient capture of data from the research process, and the comprehensible presentation of those research data for key decision making. But the maturity of informatics systems for capture and analysis of data for new modalities, especially in antibody research where processes are different, is still catching up to that for small molecules.

Considering the rate at which additional new modality types are being developed, this scientific informatics situation will likely deteriorate in...

Today's Sponsors

Today's Sponsor